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Abstract: This research work is aimed at improving health care, reducing cost, and the occurrence of
emergency hospitalization in patients with Congestive Heart Failure (CHF) by analyzing heart and
lung sounds to distinguish between the compensated and decompensated states. Compensated state
defines stable state of the patient but with lack of retention of fluids in lungs, whereas decompensated
state leads to unstable state of the patient with lots of fluid retention in the lungs, where the patient
needs medication. Acoustic signals from the heart and the lung were analyzed using wavelet
transforms to measure changes in the CHF patient’s status from the decompensated to compensated
and vice versa. Measurements were taken on CHF patients diagnosed to be in compensated and
decompensated states by using a digital stethoscope and electrocardiogram (ECG) in order to monitor
their progress in the management of their disease. Analysis of acoustic signals of the heart due to the
opening and closing of heart valves as well as the acoustic signals of the lungs due to respiration and
the ECG signals are presented. Fourier, short-time Fourier, and wavelet transforms are evaluated to
determine the best method to detect shifts in the status of a CHF patient. The power spectra obtained
through the Fourier transform produced results that differentiate the signals from healthy people and
CHF patients, while the short-time Fourier transform (STFT) technique did not provide the desired
results. The most promising results were obtained by using wavelet analysis. Wavelet transforms
provide better resolution, in time, for higher frequencies, and a better resolution, in frequency, for
lower frequencies.
Keywords: acoustic signals of heart and lungs; congestive heart failure; compensated and decompensated;
wavelet transform
1. Introduction
Congestive heart failure (CHF) is the chronic medical condition which is generally characterized
by the inability of the heart to pump a sufficient quantity of oxygen-rich blood to the body.
This insufficiency can result in an excess fluid buildup within the body. The excess fluid pressure causes
shifts into the interstitial spaces, including the lungs, which lead to a condition called pulmonary
edema. The fluid buildup can also lead to pleural effusion, shortness of breath, and fatigue; however,
the presence of these symptoms or lack thereof does not confirm or refute the diagnosis of heart failure
due to their lack of specificity [1].
CHF is one of the leading global causes of death with nearly 287,000 deaths occurring each
year [2], translating into an annual estimated cost of $32 billion. Costs include health care services,
heart failure treatment, and employee absences from work. A home monitoring system could provide
a method for early detection of the retention of fluid in the lungs and the reduced efficiency of the heart
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by measuring the acoustic and electrical signals as part of a regular monitoring regime. Acoustic and
ECG sensor based methods that may lead to such an improvement in care are described in this article.
Currently, congestive heart failure is diagnosed by the presence of a combination of symptoms,
which include determining the presence of excess fluid in the body (peripheral edema) and lungs
(pulmonary edema), along with the associative abnormalities in functioning of the heart. The methods
used to assess the presence of an increase in lung water include an examination of the acoustics of the
heart and lungs, whereas the excess of body fluid is determined by the appreciation of distended neck
veins, and leg swelling. However, many of the symptoms caused by congestive heart failure alone do
not provide enough information to make an accurate diagnosis of the condition.
Currently, the approach used to monitor CHF patients is to collect daily weight measurements.
Most patients develop symptoms around three days before hospitalization. However, this can be
mitigated with proper adjustment of diuretic medication(s) [3]. Another currently used technique
for CHF monitoring is to measure the electrical impedance of lung fluid between the leads of a
pacemaker, or other implanted cardiac devices [4–6]. This signal begins to fall 11–15 days prior
to the symptom onset, and is 77% sensitive in detecting hospitalization (as opposed to weight
measurement, which is only 23% effective). This improved diagnostic ability was based on outcomes
from the MIDHeFT (Medtronic Impedance Diagnostics in Heart Failure Trial) [5] and FAST (fast
accumulations status trial) [6] trials in humans. Sensitivity improvements were realized by measuring
the impedance between the left ventricular (LV) lead and the casing since this lead was closer to
the lungs. Additionally, trials in canines demonstrated that ambulatory monitoring of intra-thoracic
impedance is a stronger indicator of the pending onset of heart failure [7,8] than other methods, such
as weight gain. Pacemakers are implanted under the skin near the collarbone to monitor the electrical
signals of the heart. Signal processing based on wavelet analysis and Hilbert-Huang transformation
(HHT) is done on the electrocardiogram (ECG) signals [9] that are helpful in monitoring the heart
signals. Congestive Heart Signals classification was done by analyzing long record ECG and its Heart
Rate Variability (HRV) signal [10]. A key limitation of most of the approaches mentioned above is
that they are limited to individuals with implanted devices. It is thus impractical for most patients.
The limitations mentioned above calls for the need for an external method that can be used to monitor
lung fluid retention. Currently, this is done through the use of a stethoscope.
One method that may be used to detect the presence of fluid involves the use of acoustic sensors
that can detect changes in sound waves produced by fluid turbulence in the heart and lungs. Sound
waves produced by the opening and closing of valves in the heart will propagate differently through
lungs filled with air than in condition when filled with a viscous fluid. These differences are utilized
by physicians to ascertain whether a person is healthy or suffering from an abnormality in heart or
lung function. Stethoscopes are used to identify these sound differences to help identify the abnormal
condition. However, the current methods of diagnosis are dependent on the skills and hearing ability
of the attending physician. A home-based monitoring approach that uses automated signal processing
is proposed to help to reduce the variability in classification and diagnosis.
Variability, among the individual beats and throughout the day is another marker of cardiac health.
Specifically, changes in heart rate over time are indicative of a healthy individual, while the absence of
such variability is associated with a greater the risk of abnormal heart function. However, such heart
rate variations pose a challenge from a perspective of data normalization and comparison. Careful
study and understanding of normal variations can thus provide insight for future measurements.
Jos Williams, Pio Poblete, and Hubert Pipberger studied day-to-day variations in a study conducted
in 1972 on 20 subjects [11]. In the study, mean and maximal day-to-day variations of durations and
amplitudes of different deflections of scalar leads as well as variations of directions and magnitudes of
several QRS (A part of ECG waveform that is caused due to ventricle depolarization and repolarization
of atria) and T spatial vectors (A part of ECG waveform that is caused due to ventricle repolarization)
were studied using computer techniques for measurement and analysis [11].
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The major goal of this research is to determine whether acoustic monitoring methods can aid
in deriving a single step systematic approach to improve our understanding and the reliability of
measurements for Congestive Heart Failure.
In an effort to better understand the natural variability in heart and lung sounds, and to establish
a baseline requirement for sensitivity, initial measurements were taken on healthy subjects over
several sessions. Data was subsequently collected from CHF patients over multiple sessions in
both compensated and decompensated stages to compare their heart rate variability of healthy and
CHF patients, as well as the changes in heart and lung signals when fluid retention has occurred.
A significant variability was observed among patients; this variability is so large that variations in
measurements across a broad group of people with different body shapes can exceed variations of the
condition in individual patients. Multiple sessions with the same subject are thus important so that
a personalized level of variability can be determined.
Another objective of this research is to facilitate the home monitoring of CHF by the patients
themselves so that the results can be transmitted to health care providers on a real-time basis, thus
potentially reducing the number of hospital visits and the associated costs. This information should
also help the healthcare provider to make requisite interventions on a timely basis and to be able to
inform patients about their condition remotely.
2. Materials and Methods
A change in lung sounds can be detected by using a stethoscope that could be a signal of the
onset of pulmonary congestion/edema [12]. One methodology for examining the lung sound could
be to ascertain the pattern of lung sounds, known as crackles or rales, which were derived from
the re-expansion of individual pulmonary alveoli that have been filled with interstitial fluid. These
could thus be a significant source of broadband noise and an effective indicator of the condition of
pulmonary edema.
Along with the above, ECG data is collected as a means of controlling where abnormalities in
stethoscope measurements can be resolved to illustrate their non-correlation component with an
abnormal heart rhythm. If the ECG data has consistent traits from two different sets of recordings
on the same subject taken at different times, and the acoustic signals are varying, then it could be
effectively assumed with a fair degree of confidence that the acoustic properties are impacted by some
other parameter [13]. In this study, the ECG signals have not been used to reject any measurement that
has false acoustic traits. The reason is that measuring the acoustic signals of both the heart and lung
yields two data sets that are indicative of changes in the patient conditions that support each other.
Heart sounds are in the range of 20–150 Hz and overlap breathing sounds [14]. Thus, heart sounds
interfere with the measurement of sounds generated by breathing [15]. Many studies have been done
with heart and lung sound separation techniques. While heart and lung sounds have independent
source signals, due to multiple reflections from lung tissues the two sounds measured at the surface
appear to be a convoluted mixture [16]. The heart sounds are non-stationary signals, and thus could be
ascertained on the time-frequency model [17]. Holding one’s breath results in obtaining heart signals
without the interference from the lung signals that are generated by breathing.
Lung sounds are created by inspiration and expiration cycles, but they may vary based on the
pathological and physiological condition of the body. These sounds, when mixed with heart sounds at
low frequencies, pose a critical challenge in discriminating the points of origin [18].
The current method of diagnosis is limited to the skills and experience of the attending physician(s)
and even a highly trained auscultologist may not be able to ascertain important time events and features
such as frequency change [19]. Much of the research to date classifies time durations of a typical
heartbeat. Currently, congestive heart failure is diagnosed by the combination of signs and symptoms,
which include extra fluid in the lungs and abnormal heart sounds. The methods used to find these
signs are: the examination of the acoustics of the heart and lungs, as well as distended neck veins,
leg swelling, and generated cardiac pulses. However, many of the signs created by congestive heart
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failure alone do not provide enough information to make an accurate diagnosis. This paper proposes a
method to detect the differences in stages of pulmonary congestion within a CHF patient using ECG
and acoustic signals.
2.1. Digital Stethoscope
A digital stethoscope from Thinklabs (Model DS32A, Thinklabs, Centennial, CO, USA) is used
for making the acoustic measurements of both the lungs and heart. The elements of this electronic
stethoscope include a transducer, amplifier, filtering, and audio input/output. The stethoscope includes
ambient noise rejection. It amplifies the captured signal to ~50 times that of the signal observed with
a typical unaided ear. The full spectral range of human hearing is from ~20 Hz to ~20 kHz. The nominal
frequency range of sounds produced by the human heart is ~20 to ~200 Hz. Most of the energy lies
below 100 Hz. The nominal frequency range of human lung sounds is ~25 to ~1500 Hz. The “bell mode”
of the digital stethoscope has a filtered frequency range of 20–650 Hz. In the “diaphragm mode”, the
range is from 20 to 2000 Hz. The stethoscope rejects background noise from the external environment
and captures and stores the signal electronically. The stethoscope captures signals in the range from
15 Hz to 20 kHz.
The signal to noise ratio (SNR) computed at zero gain for the two modes (bell/diaphragm) is in
the range of 12 dB to 18 dB. The SNR at maximum and intermediate values of gain for the two modes
(bell/diaphragm) and for the various locations of the digital stethoscope is in the range of 26 dB to
45 dB. A block diagram of a digital stethoscope is shown in Figure 1.
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penalty. It was assessed that the subject was healthy enough to be a participant in this research before
the research took place.
2.3.2. Procedures for Measurement
Each session required approximately 30 min for data collection. Participants were taken through
the consent process and evaluated for inclusion criteria after consenting and taking a brief survey.
The participants were then asked to place their hands on two electrodes of the Alivecor Heart
monitoring system ECG device, while acoustic measurements were taken of the heart and lungs.
A stethoscope was attached on a chest wrap with such tightness that the transducer was snug on the
chest in a similar manner to a heart rate chest strap. The acoustic signals were measured at locations A,
B, C, D, and E, as shown in Figure 2.
Electrical and acoustic signals were recorded and later analyzed. A minimum of two sessions per
subject was desired, with no more than seven sessions in total. Data was taken from the subject in the
form of cardiac electrical signals, via ECG, cardiac acoustic signals, via stethoscopes, and acoustic lung
signals, via stethoscopes. The data recorded was for approximately 24 s intervals. Fourier analysis
was the first signal processing tool that was performed on the data. Additionally, short time Fourier
transforms and Wavelet transforms were applied to our data.
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Figure 2. Overview of Stethoscope placement locations.
With the ECG running, measurements were taken during breath inhalation and exhalation for
acoustic lung signals with the digital stethoscope. The ECG monitor used two electrodes in direct contact
with the skin. The ECG electrodes were fixed during five separate readings recorded for each session.
2.3.3. Measurement of Lung Acoustics and Heart Acoustics
The first measurement was performed with one stethoscope placed on the front left side of the
chest above the pectoral muscle (location A in Figure 2), and with the subjects’ hands placed on two
electrodes of the Alivecor heart monitoring machine. The stethoscope was set to diaphragm mode
with gain adjusted to avoid signal saturation. Similarly, four other measurements were performed at
locations B, C, D and E in the figure. The subject was asked to take deep, easy breaths for each of the
measurements and hold it for approximately 24 s. Subjects were asked to inhale and exhale for four
seconds during the measurement of lung signals so that the lung signals were amplified with respect
to the heart signals.
The measurement of heart acoustic signals was similar to those of lung signals except for the
setting of the stethoscope and the manner in which measurements were performed. The stethoscope
was set to bell mode with the gain again adjusted to avoid the saturation of the signal. Subjects (healthy
people and CHF patients) were asked to hold their breath for 24 s (if possible) during the measurement
of the heart so that their lung signals did not interfere with the heart signals.
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2.3.4. Data Management
Recordings of the subject’s sessions were archived using only a number associated with the
individual’s records. A separate notebook with each subject’s name and relation to the numbered
recordings is kept in a locked filing cabinet. Electronic data is stored in a computer with password
protection. Only those that are directly involved in the research and specified in the consent form as
principle investigators above have access to the data. Once the study has ended, all identifiable
information, including the codes, will be destroyed. The notebook with correlated code subject
identification will be shredded and properly disposed of via confidential record standards. The data
is reviewed and visible to only Prof. Kimberly Newman, Prof. Frank Barnes, Dr. Carlin Long, and
Pratibha Sharma. There are no foreseeable outcomes that would impact the rights or welfare of the
research subjects.
3. Signal Processing and Results
Sounds in the heart are generated by turbulence resulting from the opening and closing of the
heart valves. When fluid begins to accumulate in the lungs there is a deviation in heartbeat from the
nominal healthy condition, or from earlier conditions in CHF patients. As fluid in the lungs increases,
the sounds are described by physicians as crackles. Heart sounds measured on the chest surface
propagate through and are reflected by several media, including heart and lung tissue, fluid or air
inside the lungs, bone, cartilage, and fatty tissues. The data was analyzed using Fourier transform,
Short time Fourier transform and Wavelet transform.
In this study, heart sounds were measured and recorded in healthy, compensated, and
decompensated CHF patients. The data from different individuals was analyzed full length signals of
24 s by plotting the power spectra. The calculated values for the discrete Fourier transform was made
using a fast Fourier transform algorithm. The heart, signals were measured up to a maximum frequency
of 2 kHz and then the power spectra were plotted. Visually, the plots, observed show overlapping
features in the power spectra among the three groups in almost all frequency bands except 350 to 400 Hz.
Discrimination criteria were identified by dividing the observed frequency power spectra into
frequency bands, and by comparing the power at different levels with respect to a reference level,
which was normalized iteratively to the maximum power for the three groups.
When comparing the power in the different frequencies, a level set at 2% of the normalized
maximum power for the three groups of patients appeared to give the maximum discrimination
among the three groups. A summary of the results are shown in Figure 3.
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Visually, at the level of 2% of the normalized maximum power spectra, the largest differences
in the normalized power spectra between the different groups in the range for frequencies
from 300 Hz to 600 Hz was observed. There is one healthy patient whose results are in the frequency band
from 350 to 400 Hz, whereas the rest of the data in the range from 300 Hz to 600 Hz are for CHF patients.
The 2% criterion identifies signals in the band of frequencies from 100 Hz to 800 Hz that seems to
follow the results of Yongyudh’s paper [16]. At that level the data from healthy patients are largely
between 100 Hz and 300 Hz, and CHF patients’ data are at higher frequencies. The results show that
Fourier transform was successful in predicting approximately 55% for decompensated condition and
around 75% for compensated condition in patients. In the measured data, there were two exceptions
where healthy and CHF patients overlap. However, variability in the patients’ physiques, eating
habits, heart variability, lung capacity, body fat, etc. affect the consistency of these results. For example,
a small person with small lungs would be expected to have higher resonated frequencies than a large
person with big lungs. Thus, in this study, the focus of the analysis was on the same CHF patients,
were multiple measurements that had been made on different days.
Using a wavelet transform (WT) better time resolution is achieved for higher frequencies and
better frequency resolution for lower frequencies than the Fourier transform method. The Fourier
transform gives good resolution in frequency, but doesn’t give any information about the temporal
spread, whereas the WT gives better temporal spread with the frequency content. The WT permits
high frequency spectral features to be located in the time domain. To this end, high frequency features
using WT can be better located (with less relative error) than low frequency features.
The specific WT selected may be from any of hundreds of basis wavelets. The analysis in this
study began using the Haar wavelet, which has infinite support for a given number of vanishing
moments. It is well localized in time but provides poor frequency resolution. In contrast, the Shannon
(or sinc) wavelet is perfectly localized in frequency but poorly localized in time. After evaluating
several WT implementation approaches, the Daubechies wavelet was found to best distinguish
between compensated and decompensated states, and it was adopted for this study. This method has a
minimum filter length in the spatial domain for a given number of vanishing moments. The Daubechies
scaling and wavelet functions (shown in Figure 4) act as low- and high-pass filter coefficients,
respectively. Scaling and wavelet functions are convolved with the signal and down sampled by
a factor of 2 to achieve the first level of decomposed wavelet coefficients. The low pass filter coefficients
are [0.4829629131 0.8365163037 0.2241438680 −0.1294095226]. The high pass filter coefficients are
[−0.1294095226 −0.2241438680 0.8365163037 −0.4829629131].
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The four decomposed details using scaling and wavelet function shown in Figure 5 are obtained
after applying Daubechies wavelet analysis on acoustic heart signals.
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The four decomposed details are shown in Figure 6. The first one is an approximate detail obtained
by convolving our signal with a low pass filter, down sample by 2 and then convolving the result with a
low pass filter and again down sampled by 2. The second one is a diagonal detail obtained by convolving
our signal with a high pass filter, down sample by 2 and then convolving the result with high pass filter,
and again down sampled by 2. The third is a vertical detail obtained by convolving our signal with a
low pass filter, down sample by 2, and then convolving the result with high pass filter, and again down
sampled by 2. The fourth is horizontal detail obtained by convolving our signal with a high pass filter,
down sample by 2 and then convolving the result with low pass filter and again down sampled by 2.
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The detailed wavelet transforms for several decompensated, marginally decompensated,
compensated, and healthy subjects were analyzed. Figure 7 shows the diagonal coefficients for
one patient. The measurement was taken at two different times. One was taken when the patient was
in the decompensated stage and the other, at the compensated stage. The analysis was performed
for 10 s duration heart signals at location E, in order to capture approximately 10 to 12 heart beats.
The analysis was performed on the same CHF patients. Figure 7a shows the measurement of one
individual at one period of time. Figure 7b shows the same individual from Figure 7a at a later time
after the patient had been treated.
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Figure 7. (a) Diagonal details (coefficients) of heart signals measured at location E for one of the patient,
with decompensated state, as analyzed using the wavelet transform. (b) Diagonal details (coefficients)
of heart signals measured at location E for the same patient as in (a), with measurement taken at
compensated state, as analyzed using the wavelet transform.
It is to be noted that the WT details permit discrimination among the compensated and
decompensated stages. Similarly, the diagonal and horizontal details show more consistent changes
in the pattern of decompensated and compensated patients. The coefficents in the decompenated
state are broader and are more condensed as compared to the coefficients in the compensated state
for the same patient in the horizontal and diagonal representations of the data. The data show large
variation in horizontal and vertical details for the decompensated patients group when compared to
those of the compensated circumstances. There were two patients whose condition (decompensated or
compensated) were the same for both measurements. Specifically, one patient was compensated during
both measurements and another patient was decompensated for both. Excluding these two patients,
the results seem to be consistency in that the spectral pattern is maintained, with the exception of one
patient who showed a reverse trend. The results obtained from wavelet transform predicted with a
85% success rate in a patient’s condition from compenstated to decompensated states and vice versa.
Based upon the resulting patterns, a quantitative metric to distinguish changes in the condition of
individual patients was saught. The absolute value of the mean of vertical coefficients for a patient
for two different measurements of the first heart sound was calculated, lPeak, S1 is 1st sound i.e.,
caused by turbulence that results from the closure of mitral and tricuspid valves at the start of systole.
(Figure 8). Patients #5 and #7 had the same CHF condition during these measurements. Out of six
patients (excluding patients #5 and #7), patients showed a lower decompensated value of the above
metric compared to the compensated value. Patient #6 showed almost the same values in both cases,
and patient #1 is an outlier. Medically compensated means that their symptoms and exam reflect that
their CHF status is stable and essentially under control, and decompensated means they are showing
symptoms and signs on the exam that they are not under adequate medical control. We note that there
could be some variability in clinical classification. For example, a patient may not have fluid in the
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lungs and is thus is taken as a compensated case but could have accumulation of fluid in other parts of
the body that are not observed with (e.g.,) a chest X-ray. Similar results were obtained from wavelet
anaysis applied on lung signals.
Figure 8 was plotted with a small duration signal from one S1 to the next S1 for eight different
individuals. It shows the normalized mean of vertical coefficients with respect to compensated and
decompensated patients. Patients #1 and #6 were exceptions in the sense that the magnitude of
the mean of the vertical details for the compensated wavelet coefficients was greater than in the
decompensated state. Patient #5 is the one with both bars showing the compensated condition.
These experiments yield more consistent results when, instead of one heart sound, an average of
multiple heart sounds are analyzed (Figure 9). The multiple sounds cover a number n of intervals from one
S1 to the next S1. The numbers n = 1, 2, and 3 in Figure 9 represent patients #1, #6, and #7 from Figure 8.
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The other patients are not included in this figure because these three patients are representative of
the sample as a whole. It is evident from the bar graph that patient #1’s result is more consistent with
our expectation that the compensated state should show a lesser magnitude of the mean of the vertical
details. Patient #7 yielded similar results to those obtained from a single heart sound. Patient #6 is an
outlier in both cases.
3.1. Correlation with Weight
Weight data for the eight patients discussed above is provided in Table 1. Patients in the
compensated state are expected to weigh less than those in the decompensated state due to the
loss of interstitial fluid. Patient #4, who was an outlier in the horizontal and diagonal cofficients of
heart and lung signals, is consistent with the expected weight change measurements but showed
opposite results with respect to the medical terms compensated and decompensated. Patient #6 also
showed more coefficients in the compensated stage as compared to the decompensated stage, and was
consistent with the weight change measurement, however showed opposite results with respect to the
medical terms “compensated” and “decompensated”. There are 2 patients in the weight list which had
implanted cardiac devices (ICD).
Table 1. Weight measurement at two different times.
Number Status Weight-1 Status Weight-2 ICD
Patient 1 Decompensated 167 Compensated 159 Yes
Patient 2 Decompensated 240 Compensated 207 No
Patient 3 Decompensated 212 Compensated 241 No
Patient 4 Decompensated 267 Compensated 267 Yes
Patient 5 Compensated 212 Compensated 213 No
Patient 6 Decompensated 210 Compensated 230 No
Patient 7 Decompensated 166 Mildly Decompensated 179 No
Patient 8 Decompensated 190 Probably Compensated 184 No
3.2. Heart Rate Variability Results
ECG signals from eight patients were collected and analyzed. A summary of these signals are
shown in Figures 10 and 11 for two measurements taken for the same eight patients at two different
times. The ordinate in the graph has nine different beats (PQRST curve). The record for patient #2 is
missing in the first graph due to equipment failure, as is the record for patient #7 in the second graph.
Figure 10 shows the results for eight patients measured the first time and Figure 11 shows the results
from the same eight patients measured on a second, independent occasion. Figure 10 shows the results
of decompensated patients and Figure 11 shows the results of compensated patients. The curves in
Figure 10 show stable heart rates as compared to the compensated patients’ heart rates in Figure 11
with the exception of patient #3. These heart rate variability results provided the similar inference as
obtained by wavelet transform or weigh measurement. Heart rate variability goes up for compensated
patients and goes down for decompensated patients.
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4. Conclusions
The results of this study show that a combination of non invasive stethoscope measurements
and ECG signals can be used to provide information to the doctor that reflect changes in a patient’s
condition from compenstated to decompensated states and vice versa. These data are correlated
with changes in weight for the majority of the CHF patients. Wavelet analysis gives promising
results by showing consistent differences in spectra within the same individual. Wavelet decomposed
coefficients narrowed in spectra for the same duration of signals in compensated stage as compared
with decompensated stage for any given individual. Mean values of vertical coefficients taken for
1 heart beat cycle (from one S1 sound to the next S1) or over the average of multiple heart beats also
indicates the differences in compensated and decompensated conditions for the same patient. Wavelet
analysis appears to be a better approach than Fourier analysis to analyze the acoustic signals of the
heart and the lungs. It is to be noted that the collected results showed that one of the patients was not
improving during two measurements, and this was inconsistent with the medical results. However,
this patient subsequently expired. The acoustic analysis, to date, does not give a clear distinction
between groups of patients due to a large variabilty between mutiple patients, but it appears to be
a useful tool for determining the status of a given individual patient over time.
Experiments were performed to capture the acoustic and electrical signals from healthy subjects
and CHF patients by using noninvasive devices. The results can be used as a basis for analyzing
a larger data set to verify the potential value of this approach in providing doctors with a way to
monitor changes in a patient’s condition remotely.
Additionally, the analysis technique to differentiate the signals between compensated,
decompensated, and healthy people leads to the potential for the development of a wearable system
for diagnosis of fluid retention. Finally, this research result opens the door to further research in body
sensor networks, point of care devices, and provides an opportunity to create an interface for home
tele-health and improved quality of care [21].
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